News

Today, the FDA revoked the Emergency Use Authorization (EUA) which allowed for chloroquine and hydroxychloroquine donated to the Strategic National Stockpile (SNS) to be distributed and used to treat certain hospitalized patients with COVID-19 when a clinical trial was unavailable, or participation...

With the concept of on-demand medicine becoming more common in health care, a new piece in Risk & Insurance Magazine discusses what this could mean for the workers’ compensation industry. The article, entitled “Is Concierge Service a Realistic ‘Next Step’ for the Worker Advocacy Movement?”...

The COVID-19 pandemic has brought rapid changes to the workers’ comp industry, meaning companies across the field have had to develop timely responses under less-than-ideal circumstances. In a new article for Risk & Insurance Magazine, Mike Cirillo , myMatrixx President, spoke extensively...

myMatrixx parent company, Cigna is seeing a wide range of proposals throughout the states on how to address the impact on COVID-19 on the medical and workers’ compensation system. In the area of workers’ compensation benefits, most efforts today point to enactment of legislation or regulations...

The FDA has issued a warning against the use of hydroxychloroquine and chloroquine for COVID-19 outside a hospital or clinical trial setting due to the increased risk for heart rhythm issues. These medications have not been shown to be safe and effective for treating or preventing COVID-19. Earlier...

With an aging population that is increasingly choosing to stay in the workforce past the standard retirement age, new issues are emerging in the field of workers’ compensation and workplace medical management. In light of these trends, myMatrixx has published a report on this topic, titled “Preparing...

Due to the unprecedented health care challenges caused by the COVID-19 pandemic, the New York State Workers’ Compensation Board has extended the deadline for providers to obtain prior authorization for renewals of non-formulary medications. The previous deadline of June 5, 2020, has now been moved...

After alerts that it issued last fall, the FDA decided on April 1, 2020, to ask all manufacturers of products containing ranitidine to remove their products from the market. An oral histamine-2 (H2) blocker, ranitidine was available both with and without a prescription. Sold under the brand-name,...

Our “Workers’ Compensation Pharmaceuticals: Prior Authorization and High Dollar Rejections Guide” and our “Brand to Generic Reference Guide: Workers’ Compensation Pharmaceuticals” are two of the most widely used reference materials at myMatrixx. Due to the constantly changing nature...

As specialty drugs continue to become the standard treatment for many rare and chronic conditions, these newer and complex medications are also driving costs upward. In fact, Information Medical Statistics (IMS) Health estimates that specialty net spending in the United States rose from 24.7% in 2008...